Viridian Therapeutics, Inc.\DE (VRDN) Free Cash Flow: 2014-2025
Historic Free Cash Flow for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -$84.7 million.
- Viridian Therapeutics, Inc.\DE's Free Cash Flow fell 24.62% to -$84.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$326.3 million, marking a year-over-year decrease of 65.29%. This contributed to the annual value of -$232.8 million for FY2024, which is 25.81% down from last year.
- Per Viridian Therapeutics, Inc.\DE's latest filing, its Free Cash Flow stood at -$84.7 million for Q3 2025, which was down 12.36% from -$75.4 million recorded in Q2 2025.
- Over the past 5 years, Viridian Therapeutics, Inc.\DE's Free Cash Flow peaked at -$11.6 million during Q1 2021, and registered a low of -$92.7 million during Q1 2025.
- Its 3-year average for Free Cash Flow is -$61.0 million, with a median of -$62.3 million in 2023.
- In the last 5 years, Viridian Therapeutics, Inc.\DE's Free Cash Flow tumbled by 193.38% in 2023 and then increased by 27.36% in 2024.
- Over the past 5 years, Viridian Therapeutics, Inc.\DE's Free Cash Flow (Quarterly) stood at -$16.6 million in 2021, then slumped by 106.23% to -$34.3 million in 2022, then dropped by 11.01% to -$38.0 million in 2023, then crashed by 93.04% to -$73.4 million in 2024, then fell by 24.62% to -$84.7 million in 2025.
- Its last three reported values are -$84.7 million in Q3 2025, -$75.4 million for Q2 2025, and -$92.7 million during Q1 2025.